Dr Reddys Laboratories Ads Each Repr 1 Ord Inr5 (RDY) Stock
Indian pharmaceutical company manufacturing generic medicines in global markets. Here's the price, business snapshot, and what's worth knowing about Dr Reddys Laboratories Ads Each Repr 1 Ord Inr5 in October 2026.
Dr. Reddy's Laboratories Ltd (RDY) is an India‑based multinational pharmaceutical company with a market cap of about $12.19bn. It develops, manufactures and sells generics, active pharmaceutical ingredients (APIs), over‑the‑counter products and a growing biosimilars pipeline across the US, Europe, India and emerging markets. Investors should note its mix of stable revenue from established generics and potential upside from specialty products and R&D, alongside common sector headwinds such as pricing pressure, regulatory approvals, patent litigation and currency exposure. Financial performance can be cyclical and influenced by product approvals, competitive launches and government pricing policies. This summary provides general, educational information only and is not personalised investment advice; suitability depends on an investor’s objectives, time horizon and risk tolerance.
Dr Reddys Laboratories Ads Each Repr 1 Ord Inr5 (RDY) Stock Forecast
Analyst price target, next 12 months
$498.24
+3967.3% vs today's $12.25
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Dr Reddys Laboratories Ads Each Repr 1 Ord Inr5 have a consensus 12-month target of $498.24, above the current price of $12.25.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Dr. Reddy's stock due to its potential growth, with a target price of $498.24.
Financial Health
Dr. Reddy's Laboratories is maintaining strong profits and revenue, demonstrating solid financial performance.
Dividend
DR Reddy's Laboratories has a low dividend yield of 0.66%, which may not appeal to dividend-focused investors. If you invested $1000 you would be paid $6.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Generics and R&D
A broad generics franchise plus R&D into biosimilars can support revenue growth, though pricing pressure and competition may weigh on margins.
Global Footprint
Sales across the US, Europe, India and emerging markets diversify exposure but bring regulatory and currency risks investors should monitor.
Regulatory & Patent Risks
Approvals, patent disputes and pricing policies can cause share‑price volatility — follow pipeline updates and litigation developments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
